ZEAL — Zealand Pharma A/S Share News
0.000.00%
Last trade - 00:00- DKK20.13bn
- DKK6.08bn
- DKK9.21bn
Europe Research Roundup: Aixtron, Lenzing, Novo Nordisk
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Focus: Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Live Markets: Welcome to ECB week
Live Markets: Why the oil price hasn't broken higher? Soc Gen's take
Live Markets: Not as low as feared
Zealand Pharma shares drop 25% after a quarter of patients quit obesity drug trial (updated)
Zealand Pharma shares plunge 24% after survodutide side effects, efficacy disappoint
Boehringer-Zealand's obesity drug shows promise in cutting visceral, liver fat
Zealand touts promising tolerability data for obesity drug in mid-stage study
Brief: Zealand Pharma Says Phase 2 Zupreme-1 Trial Met Its Primary Endpoint
Buyback sends Zealand Pharma up 18% after sales beat
Zealand Pharma posts smaller-than-expected Q1 loss as obesity drugs advance (updated)
Brief: Zealand Pharma Q1 EBIT Loss DKK 539 Mln
Denmark's Zealand Pharma Q1 revenue rises on obesity drug progress
Zealand Pharma posts smaller-than-expected Q1 loss as obesity drugs advance
Brief: Zealand Pharma Q1 Operating Result DKK -539 Million
Brief: Zealand Pharma Initiates $200 Mln Share Buy-Back Program